Sanofi files suit in the U.S. to defend its patent rights on Lantus®.
Sanofi filed a patent infringement suit against Merck Sharp & Dohme Corp. on August 8, 2017 in the United States District Court for the District of New Jersey. In its suit Sanofi alleges infringement of two patents.
The suit was triggered by a notification received from Merck in late June, in which Merck stated that it had filed an NDA (505(b)(2) New Drug Application) with FDA for an insulin glargine vial drug product. Merck also stated that its NDA included a paragraph IV certification challenging all of the Sanofi patents then listed in the FDA Orange Book for Sanofi’s Lantus® and Lantus® SoloStar® products.
Follow us on Twitter and Facebook for updates on the latest pharmaceutical and biopharmaceutical manufacturing news!
Filed Under: Drug Discovery